Insulin resistance in Graves' disease: a quantitative in-vivo evaluation

Eur J Clin Invest. 1988 Dec;18(6):607-13. doi: 10.1111/j.1365-2362.1988.tb01275.x.

Abstract

Hyperthyroidism is considered to be an insulin-resistant state, but a quantitative evaluation of some action of insulin is still lacking. We performed euglycaemic clamp at about 350 and 7000 pmol l-1 plasma insulin concentration in combination with the 3H-glucose infusion in 12 patients with Graves' disease and in 12 matched controls. Fasting plasma insulin (126 +/- 6.5 vs. 77.5 +/- 5.7 pmol l-1; P less than 0.001), C-peptide (502 +/- 36 vs. 363 +/- 41 pmol l-1; P less than 0.001) and glucagon (47 +/- 3.3 vs. 33.3 +/- 3 pmol l-1; P less than 0.01) were significantly higher in hyperthyroids than in euthyroids. Basal hepatic glucose production was significantly higher in hyperthyroids than in euthyroids (18.3 +/- 1.4 vs. 9.2 +/- 0.5 mumol l-1; P less than 0.0001), and its suppression during physiological hyperinsulinaemia was only 50% in hyperthyroids. Glucose utilization and suppression of lipolysis were normally stimulated by insulin. All parameters altered during hyperthyroidism were normalized during methimazole-induced euthyroidism. We conclude that insulin resistance involves mainly glucose rather than lipid and is selective at the hepatic level.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Glucose*
  • C-Peptide / blood
  • Female
  • Glucagon / blood
  • Glucose / biosynthesis
  • Graves Disease / physiopathology*
  • Humans
  • Insulin / blood*
  • Insulin / metabolism
  • Insulin Resistance*
  • Insulin Secretion
  • Liver / metabolism
  • Male
  • Middle Aged

Substances

  • Blood Glucose
  • C-Peptide
  • Insulin
  • Glucagon
  • Glucose